“…Moreover, a range of studies have found that the metabolic parameters derived from PET imaging could significantly differentiate the HER2 expression status in breast cancer and colorectal cancer, which also suggested that PET/MRI may be used in predicting HER2 status and guiding the antibody-drug conjugate therapy for BLCA. 36 , 37 …”